Currax Announces Outstanding 2024 Financial and Operational Performance

Worldwide demand for CONTRAVE® / MYSIMBA® drove revenue growth of over 50% for the second year running

Currax meets all strategic objectives in preparation for long-term growth 

BRENTWOOD, Tenn., Jan. 10, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty pharmaceutical company with over 25 products, including the number one branded oral weight loss medication CONTRAVE^® (naltrexone HCl/bupropion HCl), today announces 2024 over-performance for revenue, demand and achievement of key operational milestones. 

For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024. These outsized results were driven by increased patient demand, improved access to CONTRAVE in the United States, and ongoing expansion into additional markets. Global demand swelled to over 2.2 million units and CONTRAVE®/MYSIMBA® is now available in over 50 countries. The acceleration in revenue led to positive EBITDA resulting an increase in available cash for re-investment into enterprise value initiatives. As demand surges, Currax will expand its U.S. field force by approximately 25% in Q1 2025.

Operationally, the completion and approval of a second manufacturing facility for CONTRAVE was a key milestone for the business. This site more than doubles Currax's capacity to produce CONTRAVE and ensures the long-term continuity of global supply. This capability provides a competitive advantage to the Company, particularly while other anti-obesity treatments continue to struggle with consistent supply.

Currax launched the INFORMUS Cardiovascular Outcomes Trial (NB-CVOT3) in January of 2024 and has enrolled over 2,600 of the 8,600 patients targeted for the trial. This trial will further characterize the cardiovascular safety of CONTRAVE in an enhanced population. The company continued its commitment to ongoing cardiovascular safety through the completion of a Health Outcomes Analysis (HOA) whereby the positive results were presented at poster session at the International Society for Pharmacoepidemiology (ISPE) conference.

The unbranded "Quiet the Food Noise" campaign launched in September 2024, and a Currax video series was published. The Company's presence in the news accelerated and Currax was featured in major media outlets including CNBC, NYSE, Bloomberg, and many others. Currax finished the year by launching the "Cravings Don't Own Me" television advertising campaign which is receiving positive initial response. This year the Company will be expanding its omnichannel programs, improve patient experience platforms, and increase engagement with Key External Experts, Patient Advocacy Groups, and Healthcare Professionals.

In 2025 and beyond, the obesity market is expected to continue its momentous growth, and the Company will actively seek out business development opportunities. Currax and CONTRAVE are playing an integral role in this historic market expansion. CONTRAVE is the only treatment in its class, the Reward System Regulator class (RSR), and is an important therapeutic option for physicians and patients. The positive trends in Currax profitability and available cash provide capacity for ongoing investment in both short and long-term enterprise value driving initiatives.

"With patients having more options than ever, the market for Anti-Obesity Medications (AOMs) has become the fastest-growing pharmaceutical market in history. U.S. prescription volume is now 4x the size relative to the end of 2023," said George Hampton, Currax President and CEO. "Our success is a result of being patient focused. The more our patients succeed, the more we succeed as an organization. We are building a great company, and we have ambitious goals for our future."

Media Contact
Hope Mueller, SVP Corporate Development and Strategy
hmueller@curraxpharma.com

About Currax:

Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE^® (naltrexone HCl/bupropion HCl), ONZETRA^® Xsail^® (sumatriptan nasal powder), Silenor^® (doxepin), Treximet^®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet^®. For more information, please visit www.curraxpharma.com.

About CONTRAVE:

CONTRAVE^®, is an extended-release fixed-dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes.

IMPORTANT SAFETY INFORMATION 
CONTRAVE can cause serious side effects including: 
Suicidal thoughts or actions: One of the ingredients in CONTRAVE is bupropion. Bupropion has caused some people to have suicidal thoughts or actions or unusual changes in behavior, whether or not they are taking medicines used to treat depression. Bupropion may increase the risk of suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. If you already have depression or other mental illnesses, taking bupropion may cause it to get worse, especially within the first few months of treatment.

While taking CONTRAVE, you or your family members should pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when you start taking CONTRAVE or when your dose changes.

Stop taking CONTRAVE and call a healthcare provider right away if you or your family members notice any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempts to commit suicide; depression; anxiety; feeling agitated or restless; panic attacks; irritability; aggression, anger, or violence; acting on dangerous impulses; an extreme increase in activity and talking; other unusual changes in behavior or mood; trouble sleeping.

CONTRAVE is not approved for use in children under the age of 18.

Do not take CONTRAVE if you have uncontrolled high blood pressure; have or have had seizures; use other medicines that contain bupropion such as WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, APLENZIN and ZYBAN; have or have had an eating disorder called anorexia or bulimia; are dependent on opioid pain medicines or use medicines to help stop taking opioids, or are in opiate withdrawal; drink a lot of alcohol and abruptly stop drinking, or use medicines called sedatives (these make you sleepy), benzodiazepines, or anti‐seizure medicines and stop using them all of a sudden; are taking or have taken medicines called monoamine oxidase inhibitors (MAOIs) in the past 14 days; or are allergic to any of the ingredients in CONTRAVE.

Tell your healthcare provider about all of your medical conditions including if you have: depression or other mental illnesses; attempted suicide; seizures; head injury; tumor or infection of brain or spine; low blood sugar or low sodium; liver or kidney problems; high blood pressure; heart attack, heart problems, or stroke; eating disorder; drinking a lot of alcohol; prescription medicine or street drug abuse; are 65 or older; diabetes; pregnant or planning to become pregnant; or breastfeeding.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

CONTRAVE may cause serious side effects, including:

• Seizures. There is a risk of having a seizure when you take CONTRAVE. The risk of seizure is higher in people who take higher doses of CONTRAVE, have certain medical conditions, or take CONTRAVE with certain other medicines. Do not take any other medicines while you are taking CONTRAVE unless your healthcare provider has said it is okay to take them. If you have a seizure while taking CONTRAVE, stop taking CONTRAVE and call your healthcare provider right away.
• Risk of opioid overdose. Do not take large amounts of opioids, including opioid-containing medicines, such as heroin or prescription pain pills, to try to overcome the opioid-blocking effects of naltrexone. This can lead to serious injury, coma, or death.

Get emergency medical help right away if you take opioids and you:

• have trouble breathing
• become very drowsy with slowed breathing
• have slow, shallow breathing
• feel faint, very dizzy, confused, or have unusual symptoms
• Sudden opioid withdrawal. People who take CONTRAVE must not use any type of opioid including street drugs, prescription pain medicines, cough, cold, or diarrhea medicines that contain opioids, or opioid dependence treatments, for at least 7 to 10 days before starting CONTRAVE. Using opioids in the 7 to 10 days before you start taking CONTRAVE may cause you to suddenly have symptoms of opioid withdrawal when you take it. Sudden opioid withdrawal can be severe, and you may need to go to the hospital. Tell your healthcare provider you are taking CONTRAVE before a medical procedure or surgery.
• Severe allergic reactions. Stop taking CONTRAVE and call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the following signs and symptoms of an allergic reaction: rash, itching, hives, fever, swollen lymph glands, painful sores in your mouth or around your eyes, swelling of your lips or tongue, chest pain, or trouble breathing.
• Increases in blood pressure or heart rate. Some people may get high blood pressure or have a higher heart rate when taking CONTRAVE. Your healthcare provider should check your blood pressure and heart rate before you start taking, and while you take CONTRAVE.
• Liver damage or hepatitis. Stop taking CONTRAVE and tell your healthcare provider if you have any of the following symptoms of liver problems: stomach area pain lasting more than a few days, dark urine, yellowing of the whites of your eyes, or tiredness. Your healthcare provider may need to stop treating you with CONTRAVE if you get signs or symptoms of a serious liver problem.
• Manic episodes. Bupropion can cause some people who were manic or depressed in the past to become manic or depressed again.
• Visual problems (angle-closure glaucoma). Signs and symptoms may include: eye pain, changes in vision, swelling or redness in or around the eye. Talk with your healthcare provider to find out if you are at risk for angle‐closure glaucoma and to get treatment to prevent it if you are at risk.
• Increased risk of low blood sugar in people with type 2 diabetes mellitus who also take medicines to treat their diabetes (such as insulin or sulfonylureas). You should check your blood sugar before you start taking CONTRAVE and while you take CONTRAVE.

The most common side effects of CONTRAVE include nausea, constipation, headache, vomiting, dizziness, trouble sleeping, dry mouth, and diarrhea. These are not all of the possible side effects of CONTRAVE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information, including Medication Guide, for CONTRAVE. More information is available on www.ContraveHCP.com- Contrave HCP and www.Contrave.com- Contrave.

View original content to download multimedia:https://www.prnewswire.com/news-releases/currax-announces-outstanding-2024-financial-and-operational-performance-302347740.html

SOURCE Currax Pharmaceuticals LLC